Ascletis Pharma (HKG:1672) will present the results of its preliminary studies of its ASC47 anti-obesity drug at a congress on obesity in Malaga, Spain, according to a Tuesday filing with the Hong Kong bourse.
The company will present a poster and an oral presentation on the drug, which targets adipose tissue or body fat, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.